Archive

Medical Category: Hematology and Oncology

The HEP-COVID Trial: Therapeutic Anticoagulation in Non-Critically Ill COVID-19 Patients

Background: Patients with COVID-19 are at increased risk from thromboembolic phenomena. Patient-specific factors such as comorbidities and immobility have been linked to thrombosis. Disease-specific factors such as virus-induced endothelial changes and cytokine storm may also be triggers. Furthermore, patients with elevated …

Read More
Hematology and OncologyInfectious DiseaseThoracic and Respiratory

Rebellion21 – “HALT IT” In the Name of Evidence via J Scott Wieters, MD

In this 20-minute presentation from Rebellion in EM 2021, Dr. J Scott Wieters, MD discusses the evidence for and against the use of tranexamic acid for hemorrhage alleviation in gastrointestinal bleeding by doing a critical appraisal of the HALT-IT trial.

Read More
Abdominal and GastroinstestinalHematology and Oncology

COVID-19 and Anticoagulation: Full Dose or Prophylactic Dose?

Background: Patients with COVID-19 are at a high risk for the development of venous thromboembolic disease [Link is HERE]. Alveolar capillary microthrombi appear to be 9x more prevalent in patients with COVID-19 compared to H1N1. As a result, enhanced-dose anticoagulation …

Read More
Hematology and Oncology

REBEL Core Cast 62.0 – Hemophilia

Take Home Points Infuse factor first, investigate later Treat when bleeding is suspected, not confirmed. Have a low threshold! It is better to over treat than undertreat. Give full dose when in doubt Factor 8 = 50U/kg Factor 9 = …

Read More
Hematology and Oncology

REBEL Core Cast 50.0 – Superficial Venous Thrombosis

Take Home Points SVT >5cm or <3 cm from the SFJ should be treated with anti-coagulation.  The rate of concurrent DVT and PE in patients with SVT is 25% and 5%, respectively.

Read More
Hematology and Oncology

Sponsored

0